5 Stocks That Have the Potential to Rise 1000%

4. Rapport Therapeutics, Inc. (NASDAQ:RAPP)

On May 21, 2026, BTIG raised the firm’s price target on Rapport Therapeutics, Inc. (NASDAQ:RAPP) to $65 from $53 and maintained a Buy rating on the shares. BTIG cited clinical execution behind its more constructive stance on RAP-219 in bipolar mania, with Phase 2 topline results pulled forward to Q4 from the first half of FY27 due to steady, uniform enrollment.

On May 18, 2026, Truist assumed coverage of Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a Buy rating and a price target of $56, up from $44. Truist said its thesis remains largely consistent with its prior view, seeing RAP-219 as an attractive, differentiated epilepsy asset. The firm cited early efficacy data suggesting best-in-category potential in focal onset seizures, along with upside optionality in bipolar mania that is not reflected in current projections.

Earlier in May, Rapport Therapeutics, Inc. (NASDAQ:RAPP) reported Q1 EPS of (42c), compared to the consensus estimate of (71c). Revenue totaled $20,000, below the consensus estimate of $6M. CEO Abraham N. Ceesay said Rapport entered 2026 with “strong momentum” across the RAP-219 development program, supported by Phase 2a follow-up data in focal onset seizures and progress toward Phase 3 trials. Ceesay also cited upcoming milestones in epilepsy, bipolar mania, and the company’s long-acting injectable formulation.

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for central nervous system disorders.